Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collabora...
Texas Capital Earns Best Bank Award for Middle Market Banking in the U.S. (West) Clients cite strong satisfaction with the firm’s middle market banking DALLAS, March 03, 2026 (GLOBE NEWSWIRE) -- Texas Capital announced today that it has been named as a Best Bank – Likelihood to Recommend for Middle Market Banking in the U.S. (West) by Crisil Coalition Greenwich, recognizing the firm’s approach to serving middle market companies through its client-focused, full-service banking platform. Texas Capital serves small business, middle market and corporate clients across industries and geogra...
Enphase Energy and Capital Good Fund to Expand IQ Microinverter Deployments for Small Commercial and Residential Projects in the United States FREMONT, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ENPH), a global energy technology company, today announced a new partnership with Capital Good Fund, a nonprofit community development financial institution (CDFI) and a leading provider of solar power purchase agreements (PPAs) and leases for underserved communities in the United States. The partnership will support approximately 24 megawatts of small commercial and residential solar pr...
Moody's Ratings (Moody's) assigned a B1 rating to Matador Resources Company's ("Matador") proposed $750 million senior unsecured notes due 2034. Matador's other ratings, including its Ba3 corporate family rating ("CFR") and stable outlook, remain unchanged. The net proceeds from this debt issuance...
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven...
A director at Asa Gold & Precious Metals Ltd sold 13,355 shares at 70.600USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Enphase Energy Introduces Power Control Software to Improve Commercial Solar Economics FREMONT, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ENPH), a global energy technology company, announced that it has introduced for IQ9™ and IQ8™ Microinverter-based small commercial solar systems. The solution is designed to help installers cut costs, simplify interconnection, and unlock projects that would otherwise stall due to unfavorable project economics. Enphase Power Control™ software simplifies interconnections, reduces permitting complexity, and avoids costly utility upgrades, makin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.